Gene therapy for prostate cancer: Current status and future prospects

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate is an ideal target organ for gene therapy as a translational research. It has some advantages as follows: prostate is not a life keeping organ, can be approached easily by ultrasound as a routine clinical practice and PSA is a sensitive and useful tumor marker for the evaluation of clinical response. Intraprostatic therapeutic gene transduction (in situ gene therapy) is one of the potent therapeutic options for prostate cancer gene therapy aiming at antimetastatic benefits through the generation of immune cell-mediated cytotoxic activities that affect not only the primary tumor but also metastatic lesion. In this chapter, current outcome and future prospect of prostate cancer gene therapy are discussed.

Original languageEnglish
Title of host publicationHormone Therapy and Castration Resistance of Prostate Cancer
PublisherSpringer Singapore
Pages397-406
Number of pages10
ISBN (Electronic)9789811070136
ISBN (Print)9789811070129
DOIs
Publication statusPublished - May 11 2018

Keywords

  • Anti-tumor immunity
  • Apoptosis
  • Cancer vaccine
  • Gene therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Gene therapy for prostate cancer: Current status and future prospects'. Together they form a unique fingerprint.

  • Cite this

    Nasu, Y., & Watanabe, M. (2018). Gene therapy for prostate cancer: Current status and future prospects. In Hormone Therapy and Castration Resistance of Prostate Cancer (pp. 397-406). Springer Singapore. https://doi.org/10.1007/978-981-10-7013-6_40